<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01638143</url>
  </required_header>
  <id_info>
    <org_study_id>10-3-017</org_study_id>
    <nct_id>NCT01638143</nct_id>
  </id_info>
  <brief_title>Bio-equivalence Study</brief_title>
  <official_title>Comparison of Bioavailability of Three Different Vitamin K2 Formulations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maastricht University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to compare absorption of vitamin K2 (menaquinone-7)
      after intake of three different vitamin K2 supplements.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Several manufacturers are producing vitamin K2 raw material in different forms, namely oil
      and powder. To ensure bioequivalence of different vitamin K2 sources, the investigators are
      interested to compare the bioavailability of three different vitamin K2 formulations that are
      already commercially available. Two different oils and one powder product will be compared in
      this randomized cross-over trial. The investigators hypothesize that different vitamin K2
      sources give no differences in bioavailability of vitamin K2.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MK-7 absorption profiles</measure>
    <time_frame>9 weeks</time_frame>
    <description>The purpose of this study is to compare the MK-7 absorption profiles after intake of three different vitamin K2 (MK-7) products that are already on the market. The main study parameter is therefore the calculated AUC value from the individual MK-7 absorption profiles.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Bioequivalence</condition>
  <condition>Bioavailability</condition>
  <arm_group>
    <arm_group_label>Gnosis P-1000 capsules</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>MK-7 capsules containing 75 µg of MK-7 (source: Gnosis, Italy).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gnosis M1500 capsules</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>MK-7 capsules containing 75 µg of MK-7 (source Gnosis, Italy).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MenaQ7 M-1500 capsules</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>MK-7 capsules containing 75 µg of MK-7 (source: Nattopharma, Norway)</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>MenaQ7 M-1500 capsules</intervention_name>
    <description>The study participants will receive three different types of capsules as a single dose (75 μg of MK-7/day):
MenaQ7 M-1500 capsule
Gnosis P-1000 capsule
Gnosis M-1500 capsule
Every two weeks, participants switch to another type of capsule; the washout period will therefore be two weeks.</description>
    <arm_group_label>MenaQ7 M-1500 capsules</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Gnosis P-1000 capsules</intervention_name>
    <description>The study participants will receive three different types of capsules as a single dose (75 μg of MK-7/day):
MenaQ7 M-1500 capsule
Gnosis P-1000 capsule
Gnosis M-1500 capsule Every two weeks, participants switch to another type of capsule; the washout period will therefore be two weeks.</description>
    <arm_group_label>Gnosis P-1000 capsules</arm_group_label>
    <arm_group_label>MenaQ7 M-1500 capsules</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Gnosis M-1500 capsules</intervention_name>
    <description>The study participants will receive three different types of capsules as a single dose (75 μg of MK-7/day):
MenaQ7 M-1500 capsule
Gnosis P-1000 capsule
Gnosis M-1500 capsule
Every two weeks, participants switch to another type of capsule; the washout period will therefore be two weeks.</description>
    <arm_group_label>Gnosis M1500 capsules</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy men and women, aged between 20 and 40 years

          -  Normal body weight and height (18.5 kg/m2 &lt; BMI &lt; 30 kg/m2)

          -  Stable body weight (weight gain or loss &lt; 3 kg in past 3 mo)

          -  Written consent to take part in the study

          -  Agreement to adhere to dietary restrictions required by the protocol

        Exclusion Criteria:

          -  Abuse of drugs and/or alcohol

          -  Use of vitamin supplements containing vitamin K

          -  Soy allergy

          -  Pregnancy

          -  a history of) metabolic or gastrointestinal diseases including hepatic disorders

          -  Chronic degenerative and/or inflammatory diseases, e.g. diabetes mellitus, renal
             failure

          -  Use of oral anticoagulants

          -  Corticoid treatment

          -  Subjects with anaemia or subjects who recently donated blood or plasma

          -  Systemic treatment or topical treatment likely to interfere with coagulation
             metabolism (salicylates, antibiotics)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cees Vermeer, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VitaK BV Maastricht University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VitaK BV / Maastricht University Medical Center</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 9, 2012</study_first_submitted>
  <study_first_submitted_qc>July 10, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2012</study_first_posted>
  <last_update_submitted>July 10, 2012</last_update_submitted>
  <last_update_submitted_qc>July 10, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 11, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>vitamin K2</keyword>
  <keyword>menaquinone-7</keyword>
  <keyword>bioavailability</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin K</mesh_term>
    <mesh_term>Vitamin K 2</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

